DGAP-News

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Study RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D 24.04.2017 / 16:34 The issuer is solely responsible for the content of this announcement. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D

• Top-line results are expected in the third quarter of 2017
• 
  
• The randomized, double-blind, placebo-controlled Phase II study is evaluatin the safety and efficacy of BEKINDA^(R) (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D)
• 
  
• IBS is one of the most common gastrointestinal disorders; it is estimated that at least 30 million Americans suffer from IBS, of which over 40% are cases of IBS-D
• 
  
• If approved, BEKINDA^(R) 12 mg has the potential to be a preferred once-daily treatment for a broad segment of patients suffering from IBS-D, targeting a U.S. potential market estimated to exceed $1 billion by 2022
• 
  
• Top-line results from a Phase III study with BEKINDA^(R) 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017
• 
  
• RedHill will host an R&D Day and live webcast on BEKINDA^(R) on Thursday, April 27, 2017 in NYC, discussing the product, indications, potential markets and the ongoing Phase III and II studies for acute gastroenteritis and IBS-D, respectively
• 
  

TEL-AVIV, Israel, April 24, 2017 RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced enrollment of the last patient in the Phase II study with BEKINDA^(R) (RHB-102)^[1] 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).